oncology

The changing treatment paradigm in non-metastatic castration-resistant prostate cancer

Sponsored by Bayer Australia Limited

This article was commissioned by Bayer Australia Ltd. The treatment paradigm for men with non-metastatic castration-resistant prostate cancer (nmCRPC) is changing, thanks to the survival benefits shown with second-generation androgen receptor inhibitors (ARIs).1 However, access to these newer agents has been limited to date, due to not being listed on the Pharmaceutical Benefits Scheme (PBS) ...

Already a member?

Login to keep reading.


OR
© 2022 the limbic